Ascendis Pharma (ASND) PT Lowered to $166 at Oppenheimer, Outperform Reiterated, Skytrofa Metrics Encourage Despite Sales Miss, Remain Positive on TransCon PTH's Phase 3
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $166.00 (from $170.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
